Avalo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVTX research report →
Range $10 – $48
Price Chart
About the company
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
- CEO
- Garry A. Neil
- IPO
- 2015
- Employees
- 33
- HQ
- Wayne, PA, US
Get TickerSpark's AI analysis on AVTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $390.88M
- P/E
- -2.33
- PEG
- 0.01
- P/S
- 6606.63
- P/B
- 0.85
- EV/EBITDA
- -3.68
- Div Yield
- 0.00%
- Gross Margin
- 71.19%
- Op Margin
- -161961.02%
- Net Margin
- -150259.32%
- ROE
- -34.21%
- ROIC
- -20.89%
Latest fiscal year · YoY change
- Revenue
- $59.00K-86.6%
- Gross Profit
- $59.00K-92.7%
- Op Income
- $-72,925,000
- Net Income
- $-78,259,000-122.8%
- EPS
- $-5.84-35.2%
- OCF Growth
- -4.9%
- FCF Growth
- -4.9%
- 52W High
- $24.27
- 52W Low
- $6.53
- 50D MA
- $11.21
- 200D MA
- $15.43
- Beta
- 0.74
- RSI (14)
- 33
- Avg Volume
- 1.80M
No earnings-call transcripts are available for AVTX yet.
- Free Float
- 89.6%
- Shares Outstanding
- 57.82M
- Float Shares
- 51.81M
of shares held by institutions
136 13F filers
Buy/sell ratio 0.63. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 5.25M | ▲ 149.97K |
| Blackrock, Inc. | 4.96M | ▲ 594.05K |
| Farallon Capital Management, L.L.C. | 3.97M | ▲ 1.48M |
| Deep Track Capital, LP | 3.61M | 0 |
| Caligan Partners LP | 3.27M | ▲ 104.44K |
| Affinity Asset Advisors, LLC | 3.24M | ▲ 344.86K |
| Tcg Crossover Management, LLC | 3.02M | 0 |
| State Street Corp | 2.56M | ▼ 326.06K |
| Avoro Capital Advisors LLC | 2.38M | ▲ 44.44K |
| Vanguard Capital Management LLC | 2.26M | ▼ 8.00K |
| Nantahala Capital Management, LLC | 2.14M | ▲ 280.06K |
| Price T Rowe Associates Inc | 1.92M | ▲ 605.62K |
Held by 192 ETFs
Biggest fund positions in AVTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Jain Rita | other | 1,322 |
| Sep 30, 26 | Lind Kevin Robert | other | 1,352 |
| Sep 30, 26 | Philip Ron M | other | 1,109 |
| Sep 16, 26 | Sullivan Christopher Ryan | other | 12,394 |
| Sep 16, 26 | Sullivan Christopher Ryan | other | 12,394 |
| Sep 16, 26 | Sullivan Christopher Ryan | sell | 12,394 |
| Sep 10, 26 | Sullivan Christopher Ryan | other | 10,185 |
| Sep 10, 26 | Sullivan Christopher Ryan | other | 10,185 |
| Sep 10, 26 | Sullivan Christopher Ryan | sell | 10,185 |
| Aug 28, 26 | Doyle Mittie | other | 679 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVTX coverage
Recent articles, reports, and earnings notes.
No research on AVTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVTX report →Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 20
Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks
zacks.com · Nov 11
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
globenewswire.com · Nov 5
Avalo Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 2
Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3
seekingalpha.com · Oct 25
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
benzinga.com · Oct 23
Avalo Therapeutics (NASDAQ:AVTX) Hits New 52-Week Low – Time to Sell?
defenseworld.net · Oct 16
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.